Skip to content

Ulrike Grimberg

2 papers in the library · 703 citations · publishing 2004-2006

Papers

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study

Psychopharmacology March 1, 2004 Felix Hasler, Ulrike Grimberg, Marco A. Benz et al. 458 citations

Psilocybin, a serotonin 5-HT(2A) receptor agonist, dose-dependently altered consciousness, attention, and mood in eight healthy subjects. At medium and high doses (215 and 315 micrograms per kilogram body weight), performance on an attention test dropped by 50%, and participants reported increased emotional excitability, dreaminess, and general inactivation. Only one person experienced transient anxiety at the highest dose. Blood pressure rose modestly after the high dose, and levels of the hormones TSH, ACTH, cortisol, and prolactin increased during peak effects, with prolactin rising after both medium and high doses. No changes occurred in heart rhythm or body temperature. The authors conclude psilocybin affects core dimensions of consciousness and physiology in a dose-dependent manner and found no evidence of harm to physical health.

Effects of psilocybin on time perception and temporal control of behaviour in humans

Journal of Psychopharmacology May 20, 2006 Marc Wittmann, Olivia Carter, Felix Hasler et al. 245 citations

Psilocybin impairs the ability to reproduce time intervals longer than 2.5 seconds, to synchronize movements to beats longer than 2 seconds, and slows preferred tapping rate. These objective timing deficits are accompanied by working-memory impairments and subjective changes including depersonalization and derealization. The findings indicate the serotonin system is selectively involved in processing durations longer than 2–3 seconds and in voluntary movement speed control. The disruption of longer intervals likely results from interactions with cognitive dimensions of temporal processing via 5-HT2A receptor stimulation.